Clinical Trial Update: A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a four-week course of INCB018424 (ruxolitinib) in adults with active rheumatoid arthritis; the trial assessed safety, tolerability and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• INCB018424 (ruxolitinib) (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2015-03-23